SCHEDULE: Woodline Partners Discloses 5.6% Stake in Tango Therapeutics

Woodline Partners LP has reported beneficial ownership of 8,000,013 shares, representing 5.6% of the outstanding common stock of Tango Therapeutics, Inc., as of March 31, 2026.

Summary

• Woodline Partners LP, acting as the investment adviser to Woodline Master Fund LP and Woodline Spire Master Fund LP, has filed a Schedule 13G, indicating beneficial ownership of Tango Therapeutics, Inc. common stock.
• The filing reports ownership of 8,000,013 shares of common stock.
• This ownership stake represents 5.6% of the company's outstanding common stock.
• The reporting date for this ownership is March 31, 2026.
• The calculation of the percentage of class is based on 142,688,851 shares of common stock outstanding as of February 26, 2026, as per Tango Therapeutics' Form 10-K filed on March 5, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a significant investment by an institutional player, but it is a disclosure of existing holdings rather than new strategic information about the company's operations.

Positives

• Woodline Partners LP has taken a significant stake, indicating confidence in Tango Therapeutics' future prospects.
• The disclosure of a 5.6% ownership stake suggests a substantial investment by a recognized investment adviser.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures inherent in a Schedule 13G filing.
• Potential for increased market activity or volatility in Tango Therapeutics' stock due to the significant stake held by Woodline Partners.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Tango Therapeutics. Woodline Partners' investment implies a positive outlook on their part.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment advisers in biotechnology companies like Tango Therapeutics are common as these firms seek to capitalize on potential growth and innovation within the sector. This filing indicates Woodline Partners' strategic interest in Tango's development pipeline.

Stakeholder Impact

• Shareholders may see increased interest in Tango Therapeutics' stock due to the significant stake held by Woodline Partners LP.
• Potential for increased scrutiny of Tango Therapeutics' performance and strategy by Woodline Partners LP.

Next Steps

• Monitor future filings from Woodline Partners LP for any changes in their stake in Tango Therapeutics.
• Observe Tango Therapeutics' operational and financial performance for indicators of growth and value creation.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide new operational or financial performance data for Tango Therapeutics. While the significant stake by Woodline Partners LP is noteworthy, it does not offer sufficient new information to warrant a buy or sell recommendation without further analysis of the company's underlying business and prospects.

Keywords

Tango Therapeutics, Woodline Partners LP, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Shareholder